CA
NMTC icon

Centerpoint Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Centerpoint Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-833
Closed -$6K – 463
2024
Q1 		$6K Hold
833
– – ﹤0.01% 351
2023
Q4 		$8K Buy
+833
New +$6.14K ﹤0.01% 336

Other funds holding NMTC

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Centerpoint Advisors's NMTC Position: Q2 2024 in Review

Centerpoint Advisors sold out of NeuroOne Medical Technologies (NMTC) in Q2 2024, closing a stake of 833 shares — an estimated $6K sold.

Centerpoint Advisors first reported a position in NMTC in Q4 2023 and held it in 2 quarters. The position peaked at $8K in Q4 2023. 18 funds tracked by Wall St. Rank hold NMTC as of Q2 2024.

  • Centerpoint Advisors reported no remaining NeuroOne Medical Technologies position as of Q2 2024 after selling out during the quarter.
  • Centerpoint Advisors sold 833 NeuroOne Medical Technologies shares in Q2 2024, an estimated $6K.
  • Centerpoint Advisors first reported a position in NeuroOne Medical Technologies in Q4 2023 and held it in 2 quarters.
  • Centerpoint Advisors's NeuroOne Medical Technologies position peaked at $8K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2024.

Based on Centerpoint Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.